Abstract
The levodopa/carbidopa intestinal gel (LCIG) is an efficacious treatment for Parkinson disease. The initiation and management of the LCIG requires a streamlined approach that takes into account patient heterogeneity. In this article we outline an over arching approach to this while highlighting steps that could be potentially modified in each individual, with the ultimate goal of achieving ideal clinical outcomes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
